Literature DB >> 20464300

Modification in body weight associated with antiepileptic drugs.

Camilla N De Gaspari1, Carlos A M Guerreiro.   

Abstract

UNLABELLED: Antiepileptic drugs (AED) may cause body weight changes.
OBJECTIVE: To evaluate the dietary habits and body weight associated with AED in epileptic patients.
METHOD: Sixty-six patients were subjected to two interviews, and had their weight and body mass index calculated and compared at both times, interval between six to eight months.
RESULTS: It was observed that 59.1% showed weight gain. The patients who had no weight gain had a greater proportion of individuals who engaged in some form of physical activity. However, of the 45 patients who maintained their initial dietary and medication pattern, 75.6% recorded a weight gain. Weight gain was seen in 66.7% of patients on carbamazepine (n=18), 60% on valproate (n=5), 50% on carbamazepine+clobazam treatment (n=14), and 58.3% of patients on other(s) polytherapy (n=12).
CONCLUSION: The patient should be alerted to possible weight gain, and should be advised about dieting and participating in regular physical activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20464300     DOI: 10.1590/s0004-282x2010000200024

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  6 in total

Review 1.  Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the Way.

Authors:  Deborah R Leitner; Gema Frühbeck; Volkan Yumuk; Karin Schindler; Dragan Micic; Euan Woodward; Hermann Toplak
Journal:  Obes Facts       Date:  2017-10-12       Impact factor: 3.942

2.  Possible association between moderate intellectual disability and weight gain in valproic acid-treated patients with epilepsy.

Authors:  Yukiko Tanamachi; Junji Saruwatari; Madoka Noai; Ryoko Kamihashi; Hiromi Soraoka; Yuki Yoshimori; Naoki Ogusu; Kentaro Oniki; Norio Yasui-Furukori; Takateru Ishitsu; Kazuko Nakagawa
Journal:  Neuropsychiatr Dis Treat       Date:  2015-04-07       Impact factor: 2.570

3.  Clobazam: the phoenix drug (from the very old to the brand new).

Authors:  Carlos A M Guerreiro
Journal:  Indian J Med Res       Date:  2014-08       Impact factor: 2.375

4.  Assessment of atherosclerotic risk among patients with epilepsy on valproic acid, lamotrigine, and carbamazepine treatment.

Authors:  Nudrat A Zuberi; Mukhtiar Baig; Shazia Bano; Zehra Batool; Saeeda Haider; Tahira Perveen
Journal:  Neurosciences (Riyadh)       Date:  2017-04       Impact factor: 0.906

5.  Assessment of the biomarkers of hepatotoxicity following carbamazepine, levetiracetam, and carbamazepine-levetiracetam adjunctive treatment in male Wistar rats.

Authors:  Opeyemi Samson Osuntokun; Ademola Adeniyi Babatunde; Gbola Olayiwola; Tope Gafar Atere; Olayemi Olutobi Oladokun; Kabiru Isola Adedokun
Journal:  Toxicol Rep       Date:  2021-03-10

6.  Impact of Physical Activity and Medication Adherence on the Seizure Frequency and Quality of Life of Epileptic Patients: A Population Study in West Texas.

Authors:  YoonJung Lee; Yeseul Ahn; Luca Cucullo
Journal:  Biomed Res Int       Date:  2022-01-18       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.